相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring
Duan-fang Shao et al.
BONE MARROW TRANSPLANTATION (2022)
Characterization of drug-drug interactions on the pharmacokinetic disposition of busulfan in paediatric patients during haematopoietic stem cell transplantation conditioning
Allison Dunn et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Can Published Population Pharmacokinetic Models of Busulfan Be Used for Individualized Dosing in Chinese Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? An External Evaluation
Huiping Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations
Jinjie Yuan et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2021)
Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients
Matthijs W. van Hoogdalem et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation
Yidan Sun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
Hanen Marsit et al.
CLINICAL PHARMACOKINETICS (2020)
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population
Praveen Shukla et al.
FRONTIERS IN PHARMACOLOGY (2020)
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children
Michael Philippe et al.
BONE MARROW TRANSPLANTATION (2019)
Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis
Myeong Gyu Kim et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2-and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen
Jingjing Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases
Yasuyoshi Ishiwata et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation
Tiago Nava et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
Joy Benadiba et al.
PLOS ONE (2018)
Allometric size: The scientific theory and extension to normal fat mass
Nick H. G. Holford et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
Marc Ansari et al.
ONCOTARGET (2017)
GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation
Tiago Nava et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram
Su-jin Rhee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation
Xuemei Wu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children
M. Philippe et al.
BONE MARROW TRANSPLANTATION (2016)
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
Jeanne Palmer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Andrew C. Harris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-upaEuro
D. E. Peterson et al.
ANNALS OF ONCOLOGY (2015)
Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients
J. Yin et al.
BONE MARROW TRANSPLANTATION (2015)
Dosing algorithm revisit for busulfan following IV infusion
Yanlin Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation
Radojka M. Savic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation
Fiona L. Dignan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation
Marc Ansari et al.
THERAPEUTIC DRUG MONITORING (2013)
Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients Towards Individualized Dosing
Imke H. Bartelink et al.
CLINICAL PHARMACOKINETICS (2012)
Weight-Based Strategy of Dose Administration in Children Using Intravenous Busulfan: Clinical and Pharmacokinetic Results
Gerard Michel et al.
PEDIATRIC BLOOD & CANCER (2012)
Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
Reta Malaer et al.
PEDIATRIC TRANSPLANTATION (2011)
Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation
Imke H. Bartelink et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
Brian J. Anderson et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Busulfan in hematopoietic stem cell transplant setting
Jeannine S. McCune et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients
Juliette Zwaveling et al.
THERAPEUTIC DRUG MONITORING (2009)
Population pharmacokinetics of oral Busulfan in young Japanese children before hematopoietic stem cell transplantation
Hiroyoshi Nakamura et al.
THERAPEUTIC DRUG MONITORING (2008)
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients
Brian P. Booth et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
I. V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
L Nguyen et al.
BONE MARROW TRANSPLANTATION (2004)
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
JS McCune et al.
BONE MARROW TRANSPLANTATION (2002)
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation
AM Bolinger et al.
BONE MARROW TRANSPLANTATION (2001)
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia
KS Baker et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
